Abstract 492P
Background
Surgery is one of the necessary treatment methods for breast cancer patients. However, wound caused by surgery is the main source of clinically related stress stimulation, and can promote tumor metastasis. Currently, as an important component of the tumor microenvironment, myeloid-derived suppressor cells (MDSC) have become a hotspot in the study of tumor metastasis.
Methods
We comprehensively explored the influence of wound stress on tumor growth, EMT related metastasis, and the recruitment of MDSC in the tumor microenvironment in a subcutaneous 4T1 tumor model.
Results
We found that wound stress stimulation promoted breast cancer growth and lung metastasis in mice, and enhanced the recruitment of stressed MDSC in the tumor microenvironment. The expression of Vimentin increased, suggesting EMT transformation. In vitro, bone marrow MDSC cells from mice undertaking stress stimulation promoted the EMT transformation in 4T1. The exosomes were extracted and the expression of mmu-miR-126a-5p was low in stressed MDSC exosomes. Mmu-miR-126a-5p overexpression suppressed tumor growth, lung metastasis and EMT transformation. Through the database screening of the target gene of mmu-miR-126a-5p combined with the results of sequencing analysis, CXCL12 was predicted to be the target gene of mmu-miR-126a-5p, which was verified by double luciferase reporting assay. CXCL12 and CXCR4 were highly expressed in the wound stress stimulation model, indicating mmu-miR-126a-5p induces breast cancer EMT transformation by targeting CXCL12/CXCR4 axis.
Conclusions
Here, we found that surgical stress stimulation can elicit the recruitment of stressed MDSC in the tumor microenvironment. Reduced exosome miR-126a-5p released by stressed MDSC leads to EMT transformation of tumor cells by attenuating the inhibition of CXCL12/CXCR4 axis in 4T1 cells and ultimately promotes increased lung metastasis. From the perspective of tumor microenvironment, these findings explain the phenomenon of increased lung metastasis caused by surgical stress stimulation and optimize new targets for MDSC, thus providing new ideas for breast cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
478P - Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study
Presenter: Antonella Palazzo
Session: Poster session 04
479P - Radiomics to predict HER2 status in breast cancer brain metastases
Presenter: Gaia Griguolo
Session: Poster session 04
480P - Prognostic significance of somatic DNA gene rearrangement and structural atypia in metastatic breast cancer
Presenter: Hiroshi Tada
Session: Poster session 04
481P - Second generation oral selective estrogen receptor degraders (SERDs) in breast cancer: A systematic review and meta-analysis of clinical trials
Presenter: Maysa Silveira Vilbert
Session: Poster session 04
482P - Precision imaging with human epidermal growth factor receptor 2-positron emission tomography (HER2-PET) for refined treatment selection in patients with HER2-low breast cancer
Presenter: Siri af Burén
Session: Poster session 04
483P - Prognostic value of androgen receptor expression in patients with advanced triple-negative metastatic breast cancer treated with sacituzumab govitecan: A French multicentre retrospective study
Presenter: Monica Arnedos
Session: Poster session 04
484P - Multi-platform characterization of HER2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04
485P - A novel approach to identify subpopulation of CTCs with metastatic potential using sc-RNA-seq
Presenter: Evgeniya Grigoryeva
Session: Poster session 04
486P - The influence of NF1 germline and somatic mutations on breast cancer patient survival
Presenter: Roope Kallionpää
Session: Poster session 04
487P - Induction of an inflammatory tumor microenvironment with oncolytic virus CF33-hNIS-antiPD-L1 intratumoral injection in patients with metastatic triple-negative breast cancer (mTNBC)
Presenter: Jamie Rand
Session: Poster session 04